title: The anti-tumor properties of two tumstatin peptide fragments in human gastric carcinoma.
abstract: OBJECTIVE
  The aim was to study the anti-tumor activities and mechanisms of two synthetic peptide fragments of tumstatin (alpha3 (IV) NC1 domain) in human gastric carcinoma cells in vitro and in vivo.
  
  
  METHODS
  MTT assay and cell cycle assay were used to study the anti-tumor and anti-angiogenic activities of two peptide fragments in vitro. Apoptosis induced by the two peptide fragments was demonstrated by TUNEL assay and morphological observation. The orthotopic tumor model was established to investigate the activities of two peptide fragments in vivo. Intratumor vascularization and the expressions of VEGF, bFGF, Fas, FasL, Bax, Bcl-2, and caspase 3 were determined using immunohistochemistry and Western blot analysis.
  
  
  RESULTS
  Peptide 19 inhibited SGC-7901 proliferation and induced apoptosis both in vitro and in vivo. Notably, peptide 21 suppressed the proliferation of HUVEC-12 cells in vitro. Each peptide arrested both cell lines at the G(0)/G(1) phase of the cell cycle, and they also synergistically suppressed in vitro and in vivo tumor growth. Immunohistochemistry and Western blot analysis revealed the strong expression of Fas, FasL and caspase 3 in orthotopic tumor tissues treated with peptide 19 alone or in combination with peptide 21. Decreased expressions of VEGF and bFGF and decreased microvessel density (MVD) in orthotopic tumor tissues were seen in mice treated with peptide 21 alone or in combination with peptide 19.
  
  
  CONCLUSIONS
  Two tumstatin peptide fragments facilitate two unique antitumor activities. Thus, they are drug candidates in the treatment of gastric carcinoma.
authors.affiliation: Department of Pathology, Second Hospital of Harbin Medical University, Harbin, China.
authors.forename: Ying-jie
authors.initials: YJ
authors.lastname: Li
authors.forename: Li-chun
authors.initials: LC
authors.lastname: Sun
authors.forename: Yan
authors.initials: Y
authors.lastname: He
authors.forename: Xing-han
authors.initials: XH
authors.lastname: Liu
authors.forename: Miao
authors.initials: M
authors.lastname: Liu
authors.forename: Qi-min
authors.initials: QM
authors.lastname: Wang
authors.forename: Xiao-ming
authors.initials: XM
authors.lastname: Jin
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D001324:Autoantigens / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D024141:Collagen Type IV / Q000494:pharmacology*; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010446:Peptide Fragments / Q000494:pharmacology*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D001324:Autoantigens; D024141:Collagen Type IV; D010446:Peptide Fragments; C089942:collagen alpha3(IV) 185-203; C057112:type IV collagen alpha3 chain
references.citation: Cell. 1994 Dec 30;79(7):1157-64
references.pmid: 7528107
references.citation: Pharm Res. 2008 Dec;25(12):2731-9
references.pmid: 18551250
references.citation: Mol Med. 1995 Jan;1(2):120-2
references.pmid: 8529090
references.citation: Cell. 1996 Aug 9;86(3):353-64
references.pmid: 8756718
references.citation: J Biol Chem. 2001 Aug 24;276(34):31959-68
references.pmid: 11399763
references.citation: J Exp Med. 1971 Feb 1;133(2):275-88
references.pmid: 4332371
references.citation: Nat Med. 1995 Jan;1(1):27-31
references.pmid: 7584949
references.citation: J Biol Chem. 2004 Jan 16;279(3):2091-100
references.pmid: 14583633
references.citation: Virchows Arch. 2007 Jul;451(1):65-71
references.pmid: 17593387
references.citation: Acta Biochim Biophys Sin (Shanghai). 2006 Jul;38(7):514-21
references.pmid: 16820868
references.citation: Biochem Biophys Res Commun. 2005 Jul 29;333(2):292-8
references.pmid: 15979458
references.citation: J Biol Chem. 2000 Aug 4;275(31):23745-50
references.pmid: 10837460
references.citation: J Biol Chem. 2000 Jul 14;275(28):21340-8
references.pmid: 10766752
references.citation: J Biol Chem. 2000 Feb 18;275(7):4796-802
references.pmid: 10671513
references.citation: Nature. 2000 Sep 14;407(6801):249-57
references.pmid: 11001068
references.citation: Curr Opin Obstet Gynecol. 2003 Feb;15(1):45-9
references.pmid: 12544501
references.citation: Cell. 1997 Jan 24;88(2):277-85
references.pmid: 9008168
references.citation: J Biol Chem. 1997 Aug 15;272(33):20395-401
references.pmid: 9252346
references.citation: Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3297-306
references.pmid: 18089723
references.citation: Nature. 2004 Feb 26;427(6977):787
references.pmid: 14985739
references.citation: J Biol Chem. 1994 Oct 14;269(41):25475-82
references.pmid: 7929248
references.citation: J Biol Chem. 2004 Jan 23;279(4):2772-80
references.pmid: 14610079
references.citation: J Biol Chem. 2001 May 4;276(18):15240-8
references.pmid: 11278365
references.citation: Nat Rev Cancer. 2003 Jun;3(6):422-33
references.pmid: 12778132
references.citation: Microvasc Res. 2007 Sep-Nov;74(2-3):85-9
references.pmid: 17602710
references.citation: Blood. 2007 Aug 15;110(4):1168-77
references.pmid: 17426256